Streetbeat News

Revenues

DRCT

Direct Digital Holdings (NASDAQ:DRCT) has received unanimous bullish ratings from 5 analysts in the last three months, with an average 12-month price target of $24.5, indicating a 15.29% increase from the previous target. The company's financial performance shows strong growth and profitability, with a notable revenue growth rate of 128.87% and a high ROE of 64.34%, despite a high debt-to-equity ratio of 3.81.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 3:01 pm

PG

The analysis compares Procter & Gamble (PG) against competitors in the Household Products industry, highlighting its financial metrics, market position, and growth prospects. PG shows signs of undervaluation based on PE and PB ratios, strong profitability with high EBITDA and gross profit, but lower revenue growth compared to the industry. The company's high PS ratio suggests potential overvaluation based on sales, and its ROE indicates possible inefficiency in utilizing equity.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 3:01 pm

WBS

Webster Financial Corp (NYSE:WBS) has received mixed analyst ratings over the past quarter, with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target for WBS has slightly increased to $60.86, with analysts adjusting their ratings and price targets based on the company's performance and market conditions. Despite facing challenges such as a revenue decline of -9.9% and below-average ROE and ROA, WBS maintains a strong net margin of 28.28% and a conservative debt-to-equity ratio of 0.41.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 3:00 pm

AXP

Recent analyst ratings for American Express (NYSE:AXP) show a mix of bullish to bearish sentiments, with a notable positive shift in the 12-month price target to $227.76, up 5.5% from $215.88. Analysts from firms like Wells Fargo, TD Cowen, and RBC Capital have raised their price targets, reflecting optimism about the company's market performance. American Express's financial overview highlights a strong market presence, revenue growth, and financial performance above industry standards.

Portfolio Pulse from Benzinga Insights

April 24, 2024 | 3:00 pm

BA

SPR

Boeing announced during a conference call that enhanced quality control standards in Wichita are leading to more predictable and reduced cycle times in their factory. The company expects these improvements, which help the Spirit team prevent nonconformances, to continue.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 2:39 pm

BOF

BranchOut Food Inc. (NASDAQ:BOF) shares surged after announcing an expanded relationship with the nation's largest retailer, increasing the annualized value of commitments to over $8 million. The company's stock climbed on heavy trading volume, with over 50 million shares traded, significantly above its 100-day average. The expansion marks the third contract with the retailer, emphasizing the growth of BranchOut's private label segment and its strategic partnerships.

Portfolio Pulse from Erica Kollmann

April 24, 2024 | 2:37 pm

HUM

Humana Inc (NYSE:HUM) reported Q1 adjusted EPS of $7.23, surpassing the consensus of $6.12, with revenues of $29.33 billion, exceeding expectations and last year's $25.65 billion. The increase was attributed to higher per-member Medicare premiums and growth in Medicare Advantage membership, which rose to 6.1 million from 5.67 million in Q1 2023. Despite a previous Q4 loss, Humana reaffirmed its 2024 earnings guidance at $16 per share and raised its Medicare Advantage membership growth forecast. HUM shares fell 3.68% to $315.86 after the announcement.

Portfolio Pulse from Vandana Singh

April 24, 2024 | 2:10 pm

REGN

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced it will present new and updated data from its oncology and hematology pipeline at the ASCO 2024 Annual Meeting. This includes 17 presentations on investigational treatments like REGN7075 in combination with Libtayo for advanced solid tumors, and other therapies targeting multiple myeloma, lymphoma, and various solid and blood cancers. The presentations will showcase Regeneron's progress in developing novel treatments for over 30 types of cancer.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 2:06 pm

CGON

CG Oncology, Inc. (NASDAQ:CGON) announced that the final results of its Phase 2 trial of cretostimogene in combination with pembrolizumab will be presented at the ASCO 2024 Annual Meeting. The trial, CORE-001, focuses on a bladder-sparing therapeutic for patients with bladder cancer. The presentation will detail the trial's findings on the treatment of BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 2:04 pm

EDU

New Oriental Education & Technology Group, Inc. (NYSE:EDU) shares fell after reporting Q3 earnings per share of 63 cents, missing expectations of 79 cents, despite revenue beating estimates at $1.207 billion. The company saw significant year-over-year growth in revenues, operating income, and net income, attributed to new business initiatives and expansion in educational services. EDU expects Q4 revenues to increase by 28%-31% year-over-year.

Portfolio Pulse from Nabaparna Bhattacharya

April 24, 2024 | 2:04 pm